WANTED: Volunteers to help with research on food and digestion

  • Posted by admin

  We are developing new ways for studying what happens to food and its components – particularly carbohydrates and fats – in the stomach and bowel. We use MRI scanning, a safe and non-invasive way to see inside the bowel We will use these techniques to study healthy digestion and what goes wrong in ill […]

Read on and discuss

Results of cystic fibrosis research now available for all

  • Posted by admin

In a landmark move the Journal of Cystic Fibrosis and European Cystic Fibrosis Society have taken up the mantel of ensuring maximum dissemination of published research work.  In taking forward the original initiative here, all research studies published in the journal  by making the provision of a lay summary a requirement for the publication of the original […]

Read on and discuss

In the News – August 2013: Ivacaftor, lumacaftor, mannitol & nebulised amikacin

  • Posted by admin

CFTR Potentiator and Corrector Combinations The main event of the European CF calendar, the 36th European CF Society conference, took place in Lisbon in June. This provided an opportunity for Vertex Pharmaceuticals to present some interesting data from early-stage in vitro studies which gave a sense of the theoretical potential of combinations of Ivacaftor, Lumacaftor […]

Read on and discuss

In the News, May 2013: CFTR Modulators, Antibiotics, Mannitol, Infection Control

  • Posted by admin

Clinical Pipeline  CFTR Modulators  On April 18, Vertex Pharmaceuticals Inc. announced “headline” data from a Phase 2 study of its VX-661 “corrector” in combination with ivacaftor showing statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies of F508del. The study evaluated four dose levels of VX-661. Patients in […]

Read on and discuss

In the News: March 2013 – CFTR Modulators, Antibiotics, Mannitol, TOBI Podhaler and Colobreathe

  • Posted by admin

Clinical Pipeline CFTR correctors, potentiators, modulators At the end of February, Vertex Pharmaceuticals, Inc. announced the next phase of its ambitious clinical trials programme for their CFTR modulators. On the back of the success of ivacaftor (Kalydeco) for CF patients with the G551D mutation, the company announced a Phase 3 trial for its VX-809 (corrector) […]

Read on and discuss

AllTrials – All Trials Registered, All Results Reported

  • Posted by admin

To us at CFUnite, it seems obvious that the results of clinical trials should be freely accessible to the public. After all, it is patients who participate in the clinical trials in the first place, they deserve to know the outcome. So many would be astounded (and horrified) to find out that not all results […]

Read on and discuss

One month on….

  • Posted by Matt

It’s been a few weeks since CFUnite first launched and we hosted our first live event about the ground-breaking new drug Kalydeco. The dust has settled and so we’ve been able to take stock as we plan the next event.

Read on and discuss

CF Unite – a chance to get involved in research

  • Posted by Matt

I don’t have cystic fibrosis. I’ve met a few people that do, but I don’t have the foggiest idea what it’s like to have to count out the creon before each meal or find the time in the day to take all the meds and nebs.

I’m just a junior doctor that pretty much fell into doing CF research. But, after ‘falling into CF’ and after hours of experiments and plugging numbers into a spreadsheet, I have felt the buzz of seeing a beautiful graph showing a clear result. Sometimes there are enough of these rare moments to make a story to take to a conference to tell other scientists. That feels good too.

Read on and discuss